Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Treat-to-Target Decisions and Dilemmas

David S. Pisetsky, MD, PhD  |  Issue: July 2011  |  July 12, 2011

According to the resident, the patient, who we can call Mr. Jones, was 50 years of age and had had rheumatoid arthritis (RA) for about three years. Mr. Jones was on a stable regimen of methotrexate 15 mg per week and 5 mg of prednisone each day. The history suggested that the disease was not very active. The patient worked full time as a manager of an auto parts store and regularly golfed. When I asked the resident about the joint count, he said that the Mr. Jones had “some” tender and swollen joints.

I pressed the resident to be more specific about the actual number, indicating that, in medicine, we do not say that a patient has “some” hypertension or “some” anemia. Good care requires precise numbers, and rheumatology therefore must have its numbers. I then Googled the DAS calculator website to show the resident the picture of the “joint man,” with the essential 28 joints depicted by circles to make it clear where attention is needed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Let’s do a real joint count,” I said to the house officer, who, alas, needed a shave, “and then we can calculate a DAS.” Down the hall we went, sidestepping an old man with thick glasses and thin gray hair, shuffling along bent over a walker.

We greeted Mr. Jones, who was sitting comfortably, speaking to someone on his phone, saying quickly, “Gotta go, the doctors are here,” snapping the phone cover closed. Mr. Jones looked up and smiled, extending his hand to shake mine, clearly a sign that his disease was not too active because no one with tender joints wants to risk the pain associated with even with the gentlest clasp. Unless you knew that Mr. Jones had RA, you would probably not have expected this diagnosis. Mr. Jones looked quite healthy, and there was not even a bend or a twist of a finger joint that would be a tell-tale sign of RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When I questioned Mr. Jones about his symptoms, he admitted to few complaints, saying that he felt dramatically better compared to the time before he was on methotrexate and prednisone. I then examined him, gently palpating and compressing his joints, starting with the hands, then the wrists, elbows, shoulders, and knees, left and right, all 28 accounted for, keeping a close tally of those that were tender and swollen. I also checked the ankles and feet but left out the counting part.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Education & TrainingOpinionRheuminationsSpeak Out Rheum Tagged with:Diagnosispatient carerheumatologistTreat-to-Target

Related Articles

    Strong Support for Treat-to-Target Strategy in RA Patients

    March 16, 2020

    NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data. “The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T,…

    Twenty Questions, Part 1

    February 1, 2007

    What disease scores can teach you about rheumatology

    Readers Answer ‘Twenty Questions’

    April 1, 2007

    The March Rheuminations column, “Twenty Questions, Part 1” inspired many letters from TR readers. Here are just a few of those responses.

    Treat to Target in axSpA

    November 29, 2022

    PHILADELPHIA—Treat to target (T2T) is a common phrase in rheumatology these days—and a welcome one.1 Many of us are familiar with what T2T means in rheumatoid arthritis (RA), but we may be less sure of its meaning in axial spondyloarthritis (axSpA). At ACR Convergence 2022, Alexis Ogdie, MD, associate professor of medicine and epidemiology, University of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences